CytRx,
a biopharm research and development company specializing in cancer treatment,
was recently featured in an article by Seeking Alpha contributor Equity Options
Guru who highlights the potential of the company’s pipeline of oncology
treatment candidates.
Aldoxorubicin
is the company’s improved version of doxorubicin, a commonly used
chemotherapeutic agent saddled with significant risk of adverse events stemming
from high levels of toxicity.
To
read the full article visit: http://seekingalpha.com/article/1922201
CytRx
in early December reported positive phase 2b trial of aldoxorubicin for
first-line metastatic, locally advanced, or unresectable soft tissue sarcomas.
In the study, both an investigator assessment and a central lab review agreed
that aldoxorubicin was superior to doxorubicin. Furthermore, aldoxorubicin was
found to be safe and well-tolerated with no treatment-related deaths.
As
the article notes, shares of CytRx have soared nearly 200 percent over the past
year along the course of development of aldoxorubicin. The author suggests that
shares will head even higher in 2014 based on several upcoming anticipated
events:
• Phase 2 Trial Initiation for Kaposi’s
Sarcoma – Expected in late 2013/early 2014
• Phase 3 Trial Initiation for 2nd-Line
Soft Tissue Sarcoma – Expected during 1st quarter 2014
• Preliminary Phase 2 GBM (glioblastoma
multiforme) results – Expected during 3rd quarter 2014
• Overall survival data from Phase 2b
1st-Line Soft Tissue Sarcoma Trial – Expected during 3rd quarter 2014
Equity
Options Guru also outlines CytRx’s financial position and possible future
partnerships to strengthen product advancement.
In
conclusion, Equity Options Guru writes, “CytRx Corporation certainly seems well
on its way for future growth. The Phase 2b STS results were extremely
encouraging not only for that indication but for the applicability of
aldoxorubicin to other indications. If the company continues to execute over
the next couple of years like it has over the past couple, there is no telling
how high the share price could go.”
For
more information, visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
